Literature DB >> 27586512

The Addition of Dexmedetomidine to Analgesia for Patients After Abdominal Operations: A Prospective Randomized Clinical Trial.

Minhua Cheng1, Jialiang Shi2, Tao Gao1, Juanhong Shen2, Chenyan Zhao2, Fengchan Xi2, Weiqin Li2, Qiurong Li2, Wenkui Yu3.   

Abstract

BACKGROUND: Postoperative pain and anxiety are two common factors influencing patient's recovery. Benefits and safety in the use of sedative agents after abdominal operations to improve recovery are not well known. The present study is to evaluate the efficacy and safety of dexmedetomidine use in this population.
METHODS: A prospective randomized controlled trial of 145 patients undergoing abdominal operations was conducted in the Surgical Intensive Care Unit of Jinling Hospital between October and December 2015. Thirty-two patients were excluded, and 113 were included and divided into the experimental group (59 patients) receiving dexmedetomidine and analgesics for 72 h after abdominal operations, and the control group (54 patients) receiving only analgesics. Postoperative pain, inflammatory response, recovery of gastrointestinal function, adverse events, and sedation level were analyzed.
RESULTS: Pain scores, assessed by Prince Henry Pain Scale (PHPS), in the experimental group were significantly lower than in the control group on the first (1.53 vs. 2.07, p ≤ 0.01), second (1.07 vs. 1.63, p ≤ 0.01), and third day (1.08 vs. 1.82, p = 0.01). Time to defecation was 0.60 days shorter in the experimental group than the control group (2.51 vs. 3.11, p = 0.01). There was no significant difference between inflammatory responses in the two groups (p > 0.05). Both groups had similar blood pressure, heart rate, prevalence of bradycardia, and hypotension requiring interventions (p > 0.05).
CONCLUSIONS: The addition of dexmedetomidine to analgesia after abdominal operations is safe and could enhance gastrointestinal function recovery and pain control when monitored carefully. The capacity of dexmedetomidine to attenuate inflammatory responses requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27586512     DOI: 10.1007/s00268-016-3698-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret.

Authors:  R M Venn; M D Karol; R M Grounds
Journal:  Br J Anaesth       Date:  2002-05       Impact factor: 9.166

2.  The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis.

Authors:  Kwok M Ho; Joseph Y Ng
Journal:  Intensive Care Med       Date:  2008-06-25       Impact factor: 17.440

3.  Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations.

Authors:  U O Gustafsson; M J Scott; W Schwenk; N Demartines; D Roulin; N Francis; C E McNaught; J Macfie; A S Liberman; M Soop; A Hill; R H Kennedy; D N Lobo; K Fearon; O Ljungqvist
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

Review 4.  Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis.

Authors:  Jen A Tan; Kwok M Ho
Journal:  Intensive Care Med       Date:  2010-04-08       Impact factor: 17.440

Review 5.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.

Authors:  Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  JAMA       Date:  2007-12-12       Impact factor: 56.272

7.  Bupivacaine Versus Liposomal Bupivacaine for Postoperative Pain Control after Augmentation Mammaplasty: A Prospective, Randomized, Double-Blind Trial.

Authors:  Meghan H Nadeau; Anju Saraswat; Alexander Vasko; John O Elliott; Susan D Vasko
Journal:  Aesthet Surg J       Date:  2015-12-23       Impact factor: 4.283

Review 8.  Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit.

Authors:  Juliana Barr; Gilles L Fraser; Kathleen Puntillo; E Wesley Ely; Céline Gélinas; Joseph F Dasta; Judy E Davidson; John W Devlin; John P Kress; Aaron M Joffe; Douglas B Coursin; Daniel L Herr; Avery Tung; Bryce R H Robinson; Dorrie K Fontaine; Michael A Ramsay; Richard R Riker; Curtis N Sessler; Brenda Pun; Yoanna Skrobik; Roman Jaeschke
Journal:  Crit Care Med       Date:  2013-01       Impact factor: 7.598

Review 9.  Pathogenesis of infection in surgical patients.

Authors:  Ping Cui; Xiangming Fang
Journal:  Curr Opin Crit Care       Date:  2015-08       Impact factor: 3.687

10.  Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection.

Authors:  George E Theodoropoulos; Nikolaos A Memos; Kiriaki Peitsidou; Theodoros Karantanos; Basileios G Spyropoulos; George Zografos
Journal:  Ann Gastroenterol       Date:  2016 Jan-Mar
View more
  2 in total

1.  Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis.

Authors:  Kathleen E Wheeler; Ryan Grilli; John E Centofanti; Janet Martin; Celine Gelinas; Paul M Szumita; John W Devlin; Gerald Chanques; Waleed Alhazzani; Yoanna Skrobik; Michelle E Kho; Mark E Nunnally; Andre Gagarine; Begum A Ergan; Shannon Fernando; Carrie Price; John Lewin; Bram Rochwerg
Journal:  Crit Care Explor       Date:  2020-07-06

2.  Dexmedetomidine ameliorates muscle wasting and attenuates the alteration of hypothalamic neuropeptides and inflammation in endotoxemic rats.

Authors:  Minhua Cheng; Tao Gao; Fengchan Xi; Chun Cao; Yan Chen; Chenyan Zhao; Qiurong Li; Wenkui Yu
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.